

# Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society of Thoracic Surgery / American College of Cardiology Transcatheter Valve Therapy Registry

Sreekanth Vemulapalli MD, David Dai MS, Michael Mack MD, David Holmes MD, Fred Grover MD, Raj Makkar MD, Vinod H. Thourani MD, Pamela S. Douglas MD

On behalf of the STS/ACC TVT Registry



# Disclosures, Funding and Disclaimer

Sreekanth Vemulapalli, MD

Abbott Vascular, American College of Cardiology

This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR). The views expressed in this presentation represent those of the author(s), and do not necessarily represent the official views of the NCDR or its associated professional societies identified at [www.ncdr.com](http://www.ncdr.com).


# Background

- TAVR effectively treats patients with severe aortic stenosis
- There are recent reports of TAVR leaflet abnormalities and valve thrombosis (4DCT / TEE) or Valve Hemodynamic Deterioration (VHD) (increase in aortic valve mean gradient)
- Planned prospective studies to investigate this using advanced imaging will take years to complete
- STS / ACC TVT Registry: Collaboration of STS, ACC, CMS, FDA, hospitals, industry, SCAI, AATS, NIH, and consumer advocates
  - Unique opportunity to track current TAVR performance in the community
  - All commercial valve implantations in US
  - Linked to CMS database for long term follow up
  - Prespecified post-procedure, 30-day, 1-year transthoracic echo (TTE)
  - TTEs are site read



# Objectives and Methods


Short Term



Aim 1: Incidence of VHD  
( $\geq 10$  mm Hg  $\uparrow$  gradient)


# Objectives and Methods

## Short Term Cohort



Aim 1: Incidence of VHD  
( $\geq 10$  mm Hg  $\uparrow$  gradient)

## Long Term Cohort




# Objectives and Methods

## Short Term Cohort

Post-procedure  
Echo

30-day  
Echo

TAVR



Aim 1: Incidence of VHD  
( $\geq 10$  mm Hg  $\uparrow$  gradient)

Aim 2: 18-month  
cardiovascular  
outcomes

Mortality

Stroke

Heart failure

Re-intervention



## Long Term Cohort

TAVR

30-day Echo

1-year Echo

CMS linkage



# Objectives and Methods

## Short Term Cohort

Post-procedure  
Echo

30-day  
Echo

TAVR

Aim 1: Incidence of VHD  
( $\geq 10$  mm Hg  $\uparrow$  gradient)

Aim 3: Predictors of VHD

Backwards selection regression model

Aim 2: 18-month  
cardiovascular  
outcomes

Mortality  
Stroke

Heart failure

Re-intervention


## Long Term Cohort

TAVR


30-day Echo

1-year Echo

CMS linkage




# Study Design






# Study Design



# Study Design



# Baseline Patient Characteristics

	Short Term Cohort (N=10,099)	Long Term Cohort (N=3175)
Age (years), median (IQR)	84.0 (78.0,88.0)	84.0 (78.0,88.0)
Male sex	5182 (51.3)	1487 (46.8)
Hypertension	9003 (89.1)	2801 (88.2)
Diabetes Mellitus	3593 (35.6)	1109 (34.9)
Prior MI	2405 (23.8)	774 (24.4)
Prior stroke or TIA	1891 (18.7)	582 (18.3)
Atrial fibrillation/flutter	4146 (41.1)	1222 (38.5)
Dialysis dependent	379 (3.8)	84 (2.6)
STS PROM Score, median (IQR)	6.7 (4.5,10.0)	6.4 (4.5,9.6)
Aspirin (Discharge)	8798 (87.1)	2816 (88.7)
Warfarin (Discharge)	2510 (24.9)	780 (24.6)
Dabigatran (Discharge)	2602 (25.8)	832 (26.2)
P2Y12 inhibitor (Discharge)	6586 (65.2)	2106 (66.3)
Factor Xa inhibitor (Discharge)	373 (3.7)	59 (1.9)


# Procedure and Echo Variables

	Short Term Cohort (N=10,099)	Long Term Cohort (N=3175)
<b>Baseline echo variables</b>		
LVEF median (IQR)	58.0 (45.0,64.0)	58.0 (48.0,63.5)
<b>Procedure variables</b>		
Balloon expanding valve	8029 (79.5)	2981 (93.9)
Self-expanding valve	2068 (20.5)	194 (6.1)
Valve size = 23 mm	3273 (32.4)	1376 (43.3)
Valve size = 26 mm	4502 (44.6)	1647 (51.9)
Valve size = 29 mm	1612 (16.0)	91 (2.9)
Valve size = 31 mm	710 (7.0)	61 (1.9)
Valve in valve	486 (4.8)	137 (4.3)
<b>Postprocedure echo variables</b>		
Valve oversizing	1.2 (1.1,1.4)	1.3 (1.1,1.4)
Mean AV gradient mm Hg, median (IQR)	9.0 (6.0,12.0)	10.0 (7.0,13.0)
EOA index cm <sup>2</sup> , median (IQR)	1.0 (0.8,1.2)	0.9 (0.7,1.2)
PPM present (moderate/severe)	2957 (29.3%)	847 (26.7%)


# Incidence of VHD

VHD defined as  $\uparrow$  AS mean gradient  $\geq 10$  mm Hg

**Short Term Cohort ( $\uparrow$  gradient 0–30 days)**




**Long Term Cohort ( $\uparrow$  gradient 30 day–1 yr)**



# Landmark Cumulative Incidence of Mortality/Stroke /Aortic Valve Reintervention


Short Term Cohort (↑ gradient 0–30 days)



No. at Risk  
10099  
211


# Landmark Cumulative Incidence of Mortality/Stroke /Aortic Valve Reintervention

Short Term Cohort (↑ gradient 0–30 days)




# Landmark Cumulative Incidence of Mortality/Stroke /Aortic Valve Reintervention

## Short Term Cohort (↑ gradient 0–30 days)




## Long Term Cohort (↑ gradient 30 day–1 yr)






# Landmark Cumulative Incidence of Mortality/Stroke /Aortic Valve Reintervention

Short Term Cohort (↑ gradient 0–30 days)




Long Term Cohort (↑ gradient 30 day–1 yr)




# Landmark Cumulative Incidence of Mortality/Stroke /Aortic Valve Reintervention

Short Term Cohort (↑ gradient 0–30 days)





Long Term Cohort (↑ gradient 30 day–1 yr)




# 18-Month Outcomes

Short Term Cohort (↑ gradient 0–30 days)

Long Term Cohort (↑ gradient 30 day–1 yr)



# Factors Associated with VHD



# Summary

- There is a small but present incidence of Valvular Hemodynamic Deterioration after TAVR (defined by  $\uparrow$  AV gradient  $\geq 10$  mmHg)
  - 2.1% in the post-procedure to 30 day timeframe
  - 2.5% in the 30 day to 1-year timeframe
- VHD does not appear to be not associated with excess events
  - Cumulative incidence of a composite of death, stroke, and aortic valve re-intervention and of its components are similar between those with and without VHD
- Predictors of VHD include both patient and procedural factors
  - Patient: Male,  $\uparrow$ BMI severe lung disease,
  - Procedural: 23 mm TAVR valve, valve-in-valve,  $\uparrow$ Baseline AoV gradient, severe PPM

# Limitations

- Retrospective analysis using site reported, surveillance echo data obtained at pre-specified time points
  - Uncertain relationship to clinical events, if any
  - May also detect asymptomatic or clinically unapparent VHD
- Definition of VHD ( $\uparrow$  10 mm Hg mean gradient) is not validated
- Incidence of VHD may be underestimated due to death/reoperation before follow-up gradient measurement
  - The incidence of VHD when including death is 2–4x the rate of VHD
- Significant echo data missingness; Clinical follow-up only in CMS pts
- Absence of 4DCT/TEE to determine etiology of VHD or leaflet abnormalities

# Conclusions

- Incidence of VHD as reported in clinical practice is low; ~2%
- VHD is not clearly associated with adverse CV events
- These findings, especially patient and procedural predictors, may help to inform TAVR care including patient selection, surveillance and preventive strategies
- Large, prospective studies using advanced imaging (4DCT/TEE) are necessary to fully elucidate the incidence, mechanisms and consequences of VHD



# NCDR<sup>®</sup>

NATIONAL CARDIOVASCULAR DATA REGISTRY

